Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENCE (Canaglifl...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Circulation
Main Authors: Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Capuano, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Sun, Tao, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Brenner, Barry M., Perkovic, Vlado
Format: Artigo
Sprog:Inglês
Udgivet: Lippincott Williams & Wilkins 2019
Fag:
Original Research Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727954/
https://ncbi.nlm.nih.gov/pubmed/31291786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker